CAR T-Cell Immunotherapy for Aggressive NHL Effective, Feasible in Real-World Setting
The use of anti-CD19 chimeric antigen receptor T cells induced a nearly sixfold higher rate of complete response compared with historical outcomes in patients with refractory, aggressive non-Hodgkin lymphoma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASH 2016 Leukemia & Lymphoma News Source Type: news
More News: Cancer & Oncology | Conferences | History of Medicine | Immunotherapy | Legislation | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma